KalVista Pharmaceuticals, Inc. (KALV)
Stock Price:
$10.74 USD
-0.20 (-1.83%)
Updated Aug 4, 2020 1:46 PM EDT - Market open
Key Info
| Market Cap |
191.68M |
| Revenue (ttm) |
12.69M |
| Net Income (ttm) |
-29.12M |
| Shares Out |
17.85M |
| EPS (ttm) |
-1.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$10.74 |
| Previous Close |
$10.94 |
| Change ($) |
-0.20 |
| Change (%) |
-1.83% |
| Day's Open |
10.93 |
| Day's Range |
10.28 - 10.93 |
| Day's Volume |
22,930 |
| 52-Week Range |
5.61 - 18.96 |
More Stats
| Market Cap |
191.68M |
| Enterprise Value |
125.02M |
| Earnings Date (est) |
Sep 14, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
17.85M |
| Float |
11.06M |
| EPS (basic) |
-1.64 |
| EPS (diluted) |
-1.64 |
| FCF / Share |
-2.54 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
391,842 |
| Short Ratio |
1.98 |
| Short % of Float |
3.43% |
| Beta |
2.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.10 |
| PB Ratio |
2.09 |
| Revenue |
12.69M |
| Operating Income |
-40.53M |
| Net Income |
-29.12M |
| Free Cash Flow |
-45.04M |
| Net Cash |
66.66M |
| Net Cash / Share |
3.73 |
| Gross Margin |
-216.74% |
| Operating Margin |
-319.41% |
| Profit Margin |
-229.40% |
| FCF Margin |
-354.89% |
| ROA |
-24.05% |
| ROE |
-32.26% |
| ROIC |
-38.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$27.00*
(151.40% upside)
Low
19.0
Current: $10.74
High
33.0
Target: 27.00
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 12.69 | 16.13 | 8.39 | 1.50 | 2.13 | - | 0.03 | 0.42 | 1.54 |
| Revenue Growth | -21.31% | 92.13% | 458.11% | -29.49% | - | - | -93.01% | -73.02% | - |
| Gross Profit | 12.69 | 16.13 | 8.39 | 1.50 | 2.13 | - | 0.03 | 0.42 | 1.54 |
| Operating Income | -40.53 | -29.82 | -18.71 | -22.34 | -15.18 | -9.89 | -11.68 | -5.22 | -1.83 |
| Net Income | -29.12 | -20.82 | -15.81 | -18.60 | -11.44 | -7.23 | -13.36 | -5.68 | -2.05 |
| Shares Outstanding | 17.75 | 15.08 | 10.32 | 4.65 | 0.59 | 0.26 | 0.04 | 0.03 | 0.03 |
| Earnings Per Share | -1.64 | -1.38 | -1.53 | -4.47 | -26.17 | -34.94 | -305.33 | -187.88 | -71.96 |
| Operating Cash Flow | -44.82 | -36.37 | 10.56 | -23.72 | -13.16 | -6.37 | -11.25 | -4.86 | -1.84 |
| Capital Expenditures | -0.22 | -1.08 | -1.43 | -0.07 | -0.01 | -0.13 | -0.16 | -0.02 | -0.09 |
| Free Cash Flow | -45.04 | -37.45 | 9.13 | -23.80 | -13.17 | -6.49 | -11.41 | -4.88 | -1.93 |
| Cash & Equivalents | 67.71 | 101 | 51.06 | 30.95 | 21.76 | 0.00 | 3.95 | 9.83 | 0.00 |
| Total Debt | 1.06 | - | 0.28 | - | - | - | 6.57 | 3.06 | - |
| Net Cash / Debt | 66.66 | 101 | 50.78 | 30.95 | 21.76 | 0.00 | -2.62 | 6.77 | 0.00 |
| Assets | 92.53 | 118 | 61.39 | 34.35 | 24.75 | - | 6.64 | 10.11 | - |
| Liabilities | 8.78 | 21.39 | 34.14 | 3.02 | 61.86 | - | 11.27 | 4.26 | - |
| Book Value | 83.75 | 96.74 | 27.25 | 31.33 | -37.11 | - | -44.18 | -33.71 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
KalVista Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
56 |
| CEO |
T. Andrew Crockett |
Stock Information
| Ticker Symbol |
KALV |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KALV |
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.